PT2729170T - Variantes de anticorpos e utilizações das mesmas - Google Patents

Variantes de anticorpos e utilizações das mesmas

Info

Publication number
PT2729170T
PT2729170T PT127400927T PT12740092T PT2729170T PT 2729170 T PT2729170 T PT 2729170T PT 127400927 T PT127400927 T PT 127400927T PT 12740092 T PT12740092 T PT 12740092T PT 2729170 T PT2729170 T PT 2729170T
Authority
PT
Portugal
Prior art keywords
antibody variants
variants
antibody
Prior art date
Application number
PT127400927T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Genmab Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab Bv filed Critical Genmab Bv
Publication of PT2729170T publication Critical patent/PT2729170T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT127400927T 2011-07-06 2012-07-06 Variantes de anticorpos e utilizações das mesmas PT2729170T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504994P 2011-07-06 2011-07-06
DKPA201100519 2011-07-06
DKPA201200371 2012-05-30

Publications (1)

Publication Number Publication Date
PT2729170T true PT2729170T (pt) 2022-03-21

Family

ID=47437504

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127400927T PT2729170T (pt) 2011-07-06 2012-07-06 Variantes de anticorpos e utilizações das mesmas

Country Status (21)

Country Link
US (4) US10759867B2 (OSRAM)
EP (2) EP2729170B1 (OSRAM)
JP (3) JP6243330B2 (OSRAM)
KR (2) KR102163669B1 (OSRAM)
CN (4) CN119954941A (OSRAM)
AU (5) AU2012280222B8 (OSRAM)
BR (1) BR112014000264A2 (OSRAM)
CA (1) CA2840147A1 (OSRAM)
DK (1) DK2729170T3 (OSRAM)
EA (1) EA201400108A1 (OSRAM)
ES (1) ES2908876T3 (OSRAM)
IN (1) IN2014CN00807A (OSRAM)
MX (1) MX357944B (OSRAM)
PL (1) PL2729170T3 (OSRAM)
PT (1) PT2729170T (OSRAM)
RS (1) RS63044B1 (OSRAM)
SG (1) SG10201605572TA (OSRAM)
SI (1) SI2729170T1 (OSRAM)
UA (2) UA117901C2 (OSRAM)
WO (1) WO2013004842A2 (OSRAM)
ZA (1) ZA201309499B (OSRAM)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
JP6454547B2 (ja) * 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
KR20200120743A (ko) * 2011-07-06 2020-10-21 젠맵 비. 브이 항체 변이체 및 그의 용도
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
EP2787081A4 (en) 2011-11-30 2015-10-07 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
US20130236890A1 (en) * 2012-03-08 2013-09-12 HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells
KR102089526B1 (ko) 2012-05-10 2020-03-17 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
EP3632462A1 (en) * 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
PT2869845T (pt) * 2012-07-06 2019-12-09 Genmab Bv Proteína dimérica com mutações triplas
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
EP3721900A1 (en) 2012-08-24 2020-10-14 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc region variant
ES2984345T3 (es) * 2013-01-10 2024-10-29 Genmab Bv Variantes de la región FC de IGG1 humana y usos de las mismas
US20160031985A1 (en) * 2013-03-15 2016-02-04 Katherine S. Bowdish Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
ES2746136T3 (es) 2013-04-29 2020-03-04 Hoffmann La Roche Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
US10035848B2 (en) 2014-01-08 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof
CN105899534B (zh) 2014-01-15 2020-01-07 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
RU2698969C2 (ru) * 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
KR20160104009A (ko) * 2014-01-15 2016-09-02 에프. 호프만-라 로슈 아게 변형된 FcRn-결합 성질을 갖는 Fc-영역 변이체
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
CA2960899C (en) 2014-09-17 2021-08-17 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10865253B2 (en) * 2014-12-19 2020-12-15 Genmab A/S Rodent bispecific heterodimeric proteins
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
EP3932428A1 (en) 2015-05-21 2022-01-05 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
AU2016363770A1 (en) 2015-12-01 2018-06-28 Genmab B.V. Anti-DR5 antibodies and methods of use thereof
CN106883297B (zh) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
EP3408293A4 (en) * 2016-01-28 2019-09-11 Janssen Biotech, Inc. BIS-SPECIFIC ANTI-TNF-ALPHA / IL-17A ANTIBODIES AND ANTI-TNF-ALPHA ANTIBODIES AND METHODS FOR THEIR USE
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017177175A1 (en) * 2016-04-07 2017-10-12 The George Washington University Methods and compositions targeting retroviral latency
WO2017198731A1 (en) * 2016-05-18 2017-11-23 Genmab B.V. Antibodies and methods of use thereof in treatment of infectious disease
IL263102B2 (en) 2016-05-20 2023-11-01 Harpoon Therapeutics Inc A serum albumin-binding protein with a single site
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201900744SA (en) * 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CN110461868A (zh) 2016-11-01 2019-11-15 根马布私人有限公司 多肽变体及其用途
US10849973B2 (en) 2016-11-23 2020-12-01 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
US10440535B2 (en) 2017-01-25 2019-10-08 The George Washington University System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets
EP3580233A1 (en) * 2017-02-10 2019-12-18 Genmab B.V. Polypeptide variants and uses thereof
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
MX2019009660A (es) * 2017-02-28 2019-10-02 Bristol Myers Squibb Co Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
AU2018244574A1 (en) * 2017-03-28 2019-10-31 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
UA127586C2 (uk) 2017-03-31 2023-10-25 Ґенмаб Холдінґ Б.В. Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CN111328335A (zh) 2017-06-07 2020-06-23 根马布私人有限公司 基于突变igg六聚体的治疗性抗体
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3688023B1 (en) 2017-09-25 2025-08-27 Shihuida Pharmaceutical Group (Jilin) Co., Ltd. Methods and compositions for cancer treatment
CN111630070B (zh) 2017-10-13 2024-07-30 哈普恩治疗公司 三特异性蛋白质及使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US20210107988A1 (en) * 2018-01-24 2021-04-15 Genmab B.V. Polypeptide variants and uses thereof
JP2018138022A (ja) * 2018-02-23 2018-09-06 ゲンマブ ビー．ブイ． ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
AU2019271138A1 (en) 2018-05-14 2021-01-07 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
AU2019286396A1 (en) 2018-06-14 2020-12-17 Bioatla, Inc. Multi-specific antibody constructs
MA52945A (fr) 2018-06-22 2021-04-28 Genmab As Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
WO2020002592A1 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Traf2 inhibitors for use in the treatment of a cancer
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
MX2020013631A (es) * 2018-07-13 2021-03-25 Genmab As Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas.
EP3827024A4 (en) * 2018-07-23 2022-06-08 Chugai Seiyaku Kabushiki Kaisha TARGET CELL-SPECIFIC CYTOSOL-PENETRATING ANTIGEN-BINDING MOLECULES
WO2020061526A1 (en) * 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Conditionally activated target-binding molecules
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020067541A1 (ja) * 2018-09-28 2020-04-02 協和キリン株式会社 抗体組成物
EP3883967A4 (en) * 2018-11-16 2023-04-19 Virtuoso Binco, Inc. CD38 AND ICAM1 ANTIBODIES AND USES THEREOF
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN113453716A (zh) * 2018-12-27 2021-09-28 金德雷德生物科学股份有限公司 兽用IgG Fc变体
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
GB2599227B (en) 2019-02-21 2024-05-01 Marengo Therapeutics Inc Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
JP2022521751A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
EP3966241A1 (en) 2019-05-09 2022-03-16 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
CA3160855A1 (en) 2019-12-09 2021-06-17 Adrian Wiestner Antibodies targeting cell surface deposited complement protein c3d and use thereof
CN113121677B (zh) * 2019-12-31 2023-06-27 周易 一种得到高纯度异源抗体的方法
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN114980927A (zh) 2020-01-16 2022-08-30 健玛保 Cd38抗体的配制剂及其用途
CN114945597A (zh) * 2020-01-17 2022-08-26 艾提欧生物疗法有限公司 降低脱靶毒性的前抗体
WO2021168303A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
KR20230028242A (ko) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
WO2021227937A1 (zh) * 2020-05-11 2021-11-18 神州细胞工程有限公司 通过与改变的Fc片段形成融合蛋白增强蛋白/肽抗原免疫原性的方法
JP7048665B2 (ja) * 2020-05-22 2022-04-05 ゲンマブ ビー．ブイ． ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
WO2022000136A1 (en) * 2020-06-28 2022-01-06 Dingfu Biotarget Co., Ltd. Methods and compositions for cancer treatment
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
JP2023542080A (ja) 2020-08-26 2023-10-05 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
EP4204458A4 (en) 2020-08-26 2024-10-09 Marengo Therapeutics, Inc. METHODS FOR DETECTION OF TRBC1 OR TRBC2
AU2021351187A1 (en) 2020-10-02 2023-04-20 Genmab A/S Antibodies capable of binding to ROR2 and bispecific antibodies binding to ROR2 and CD3
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
US20250099579A1 (en) 2021-04-08 2025-03-27 Marengo Therapeutics, Inc. Multispecific molecules binding to tcr and uses thereof
CN115572331A (zh) * 2021-07-06 2023-01-06 联邦生物科技(珠海横琴)有限公司 一种具有增强FcRn受体结合的突变子
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
IL311141A (en) 2021-09-06 2024-04-01 Genmab As Antibodies capable of binding to CD27, their variants and uses thereof
US20250002600A1 (en) 2021-10-06 2025-01-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
WO2023079494A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
CA3252821A1 (en) 2022-05-12 2023-11-16 BioNTech SE LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
JP2025516631A (ja) 2022-05-12 2025-05-30 ジェンマブ エー／エス 併用療法においてｃｄ２７に結合する能力を有する結合剤
JP2025518219A (ja) * 2022-06-01 2025-06-12 ユリウス－マクシミリアンス－ウニヴェルジテート ヴュルツブルク ＦｃγＲ非依存性活性を有する抗体ベースの可溶性および膜結合型ＴＷＥＡＫ模倣アゴニスト
CN117430710B (zh) * 2022-07-21 2025-07-04 中国医学科学院医药生物技术研究所 一种针对Trop2的单克隆抗体及其应用
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof
JP2025540961A (ja) * 2022-12-02 2025-12-17 リティカ セラピューティクス，インコーポレーテッド タンパク質の内在化のための組成物および方法
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
US20250296989A1 (en) 2024-03-20 2025-09-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
WO2025221933A1 (en) * 2024-04-17 2025-10-23 Vial Health Technology Inc. Antibodies and polypeptides comprising variant fc regions
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
DE69937291T2 (de) * 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) * 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
AU6375000A (en) 1999-07-29 2001-02-19 Medarex, Inc. Human monoclonal antibodies to her2/neu
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk PROCESS FOR PURIFYING ANTIBODY
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2002096910A1 (en) 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002345673B2 (en) 2001-06-13 2007-04-26 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
PT1706424E (pt) * 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
PL1776384T3 (pl) * 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
WO2010080538A1 (en) 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
CA2614181A1 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
AU2006277117B2 (en) 2005-08-05 2013-01-10 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
MX2008009956A (es) 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
EP2087111A2 (en) 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2009006520A1 (en) 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
WO2009017394A1 (en) 2007-08-01 2009-02-05 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
WO2009089004A1 (en) * 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
DE102008039957A1 (de) 2008-08-27 2010-03-04 Continental Automotive Gmbh Verfahren zur Ermittlung eines Unfallschwerekriteriums mittels eines Beschleunigungssignals und eines Körperschallsignals
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
CN110317272A (zh) * 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
NO2344478T3 (OSRAM) 2008-11-03 2018-02-24
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
NZ604003A (en) 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
CN103153339B (zh) 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
EP3281956A3 (en) 2010-06-15 2018-04-18 Genmab A/S Human antibody drug conjugates against tissue factor
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
AU2012229048B2 (en) 2011-03-16 2016-01-21 Amgen Inc Fc variants
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
PT2869845T (pt) 2012-07-06 2019-12-09 Genmab Bv Proteína dimérica com mutações triplas
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
ES2984345T3 (es) 2013-01-10 2024-10-29 Genmab Bv Variantes de la región FC de IGG1 humana y usos de las mismas
AU2016363770A1 (en) 2015-12-01 2018-06-28 Genmab B.V. Anti-DR5 antibodies and methods of use thereof
CN110461868A (zh) 2016-11-01 2019-11-15 根马布私人有限公司 多肽变体及其用途
EP3580233A1 (en) 2017-02-10 2019-12-18 Genmab B.V. Polypeptide variants and uses thereof
UA127586C2 (uk) * 2017-03-31 2023-10-25 Ґенмаб Холдінґ Б.В. Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування

Also Published As

Publication number Publication date
CN104220093A (zh) 2014-12-17
US12049512B2 (en) 2024-07-30
ES2908876T3 (es) 2022-05-04
WO2013004842A3 (en) 2013-04-04
AU2019283809A1 (en) 2020-01-16
KR20220158849A (ko) 2022-12-01
US10759867B2 (en) 2020-09-01
EP3970746A3 (en) 2022-08-03
JP2014520788A (ja) 2014-08-25
CN106084039A (zh) 2016-11-09
UA128600C2 (uk) 2024-08-28
AU2017272140A1 (en) 2017-12-21
EA201400108A1 (ru) 2014-05-30
US20250223374A1 (en) 2025-07-10
JP6243330B2 (ja) 2017-12-06
JP2024116396A (ja) 2024-08-27
KR102163669B1 (ko) 2020-10-12
RS63044B1 (sr) 2022-04-29
US20250043018A1 (en) 2025-02-06
AU2012280222B2 (en) 2017-09-14
WO2013004842A2 (en) 2013-01-10
AU2012280222B8 (en) 2017-12-07
BR112014000264A2 (pt) 2017-02-14
EP3970746A2 (en) 2022-03-23
IN2014CN00807A (OSRAM) 2015-04-03
CN119954941A (zh) 2025-05-09
US20140242075A1 (en) 2014-08-28
AU2012280222A1 (en) 2014-01-23
JP2018035140A (ja) 2018-03-08
US20210163619A1 (en) 2021-06-03
DK2729170T3 (en) 2022-03-21
CA2840147A1 (en) 2013-01-10
AU2025204452A1 (en) 2025-09-04
CN104220093B (zh) 2020-06-16
EP2729170A2 (en) 2014-05-14
AU2012280222A8 (en) 2017-12-07
CN112239496B (zh) 2024-11-29
MX357944B (es) 2018-07-31
AU2017272140B2 (en) 2019-09-26
SG10201605572TA (en) 2016-09-29
CN112239496A (zh) 2021-01-19
ZA201309499B (en) 2017-09-27
AU2022200869A1 (en) 2022-03-03
SI2729170T1 (sl) 2022-10-28
MX2013014961A (es) 2014-08-18
UA117901C2 (uk) 2018-10-25
PL2729170T3 (pl) 2022-04-11
JP6586442B2 (ja) 2019-10-02
CN106084039B (zh) 2020-09-11
KR20140146040A (ko) 2014-12-24
EP2729170B1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
IL288203A (en) Meditops and Meditop binding antibodies and their use
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL259436A (en) Antibodies against 3angptl and their uses
DK2729170T3 (en) Antibody variants and uses thereof
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
ZA201401843B (en) Antibodies against tl1a and uses thereof
IL229844B (en) Anti-psgl-1 antibodies and their use
IL254416A0 (en) Anti-asic1 antibodies and their uses
EP2716359A4 (en) COMPLEX AND USES THEREOF
HK1197885A (zh) 抗体变体及其用途